| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,100 | ₹1.05 0% | 00% |
| - | - | 4,200 | ₹3.15 0% | 3,0000% |
| - | - | 4,300 | ₹1 0% | 2500% |
| - | - | 4,350 | ₹1.2 0% | 1,1250% |
| 2500% | ₹418 0% | 4,400 | ₹0.6 -47.82% | 2,6250% |
| - | - | 4,450 | ₹12.05 0% | 1,6250% |
| - | - | 4,500 | ₹2.5 -21.87% | 21,375-8.06% |
| 3750% | ₹375.6 0% | 4,550 | ₹16.45 0% | 1,3750% |
| 2,1250% | ₹433.15 0% | 4,600 | ₹3.3 -20.48% | 11,500-4.16% |
| 1250% | ₹248.05 0% | 4,650 | ₹6 -14.28% | 3,125-3.84% |
| 6,2500% | ₹336.7 0% | 4,700 | ₹6.2 -4.61% | 16,125-1.52% |
| 5,750-2.12% | ₹263.1 -11.97% | 4,750 | ₹8.2 -11.82% | 7,250-9.37% |
| 20,875-5.64% | ₹229.3 -3.49% | 4,800 | ₹12.45 -11.38% | 31,62511.45% |
| 13,500-2.70% | ₹178 -13.8% | 4,850 | ₹19.8 -8.75% | 19,1254.79% |
| 27,000-9.24% | ₹132 -14.45% | 4,900 | ₹32.9 0.92% | 23,250-3.12% |
| 5,000-9.09% | ₹103.45 -17.76% | 4,950 | ₹50 5.93% | 4,75011.76% |
| 83,125-5.27% | ₹68.9 -27.35% | 5,000 | ₹72.15 6.73% | 36,5001.38% |
| 16,0007.56% | ₹51.35 -26.95% | 5,050 | ₹97.95 3.1% | 2,87527.77% |
| 41,000-4.09% | ₹35.25 -32.92% | 5,100 | ₹133 3.1% | 6,875-42.70% |
| 4,0000% | ₹24.85 -35.7% | 5,150 | ₹186.25 0% | 5000% |
| 27,250-1.80% | ₹19 -32.38% | 5,200 | ₹197 0% | 1,6250% |
| 2,3750% | ₹13.15 -39.67% | 5,250 | ₹244.2 2.09% | 2500% |
| 30,1254.78% | ₹11.6 -24.91% | 5,300 | ₹290 0% | 7500% |
| 2,625-12.5% | ₹5.8 -49.56% | 5,350 | ₹333.85 0% | 2500% |
| 5,2500% | ₹8.3 -4.04% | 5,400 | ₹510 0% | 2500% |
| 1,2500% | ₹4.85 -62.54% | 5,450 | ₹430.45 0% | 1250% |
| 9,37529.31% | ₹5.9 -2.47% | 5,500 | ₹677.2 0% | 5000% |
| 1,1250% | ₹2.55 0% | 5,550 | - | - |
| 4,3750% | ₹1 -75% | 5,600 | - | - |
| 4,3750% | ₹1.8 0% | 5,700 | - | - |
| 6,0000% | ₹1 0% | 5,800 | ₹855 0% | 1250% |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
